Assuming that the difference between CLL patients and healthy people is the characteristics of B cells—neoplastic ones in the case of CLL patients versus normal B cells in healthy populations—we have used this information as indirect evidence for the possible control of the specificity of CLL-derived EVs’ effect on the secretion of IL-6 by endothelial cells. Here, IL6 is linked to B-cell chronic lymphocytic leukemia.